Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan: Clinical considerations, radiopharmacy, radiation protection, perspectives;Radioimmuntherapie mit 90Y-markiertem ibritumomab-tiuxetan: Klinik, radiopharmazie, strahlenschutz, perspektiven

NuklearMedizin

Volumn 44, Issue 4, 2005, Pages 166-177

  Schomacker K ^a,b   Dietlein, M ^a   Schnell, R ^b   Pinkert, J ^c   Eschner, W ^a   Zimmermanns, B ^a   Fischer, T ^a   Engert, A ^b   Schicha, H ^a  

^a Klinik und Poliklinik für Nuklearmedizin des UKM   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Activimeter; Ibritumomab tiuxetan; Radiation protection; Radioimmunotherapy; Yttrium 90; Zevalin

Indexed keywords

ANTINEOPLASTIC AGENT; IBRITUMOMAB TIUXETAN; INDIUM 111; MONOCLONAL ANTIBODY; RITUXIMAB; YTTRIUM;

ANEMIA; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONTINUING EDUCATION; FOLLICULAR LYMPHOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LARGE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; REVIEW; SCINTIGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; ARTICLE; LYMPHOMA; METHODOLOGY; QUALITY CONTROL; SCINTISCANNING; STANDARD;

ANEMIA; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LYMPHOMA; NEUTROPENIA; QUALITY CONTROL; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; YTTRIUM RADIOISOTOPES;

EID: 23944473672     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625104     Document Type: Review

References (54)

1. Ansell SM, Ristow KM, Habermann TM et al. Subsequent chemotherapy regimes are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3885-90.
2. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Proc Am Soc Clin Oncol 2002; 21: 14.
3. Behr TM. Quo vadis Radioimmun- und Radiopeptidtherapie? Welche Rolle spielen Sie künftig im klinischen Alltag? Nuklearmedizin 2002; 41: 230-2.
4. Behr TM, Gotthardt M, Becker W et al. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy: a review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/ Marburg experience. Nuklearmedizin 2002; 41: 71-9.
5. Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Sem Nucl Med 2004; 34 (Suppl 1) 4-9.
6. Cheson BD. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan: future directions. In: Cheson BD, Leonard JP, Raubitschek A et al. (Hrsg): Ibritumomab tiuxetan (Zevalin) in non-Hodgkin's lymphoma. The Oncology Group 2003.
7. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. International J Oncol 1999; 15: 1017-25.
8. Conti PS. Radioimmuntherapy with yttrium-90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Sem Nucl Med 2004; 43 (Suppl 1) 2-3.
9. 90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy: results from a Zevalin imaging registry. Blood 2004; 104, 4570.
10. Czuczman M, Witzig TE, Gaston I et al. Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood 2002; 100: 357a.
11. Emmanouilides C, Murray JL, Vo K et al. Earlier treatment with Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmuntherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy. Blood 2003; 102: 4949.
12. Fischer M, Behr T, Grünwald F et al. Leitlinie für die Radioimmuntherapie des rezidivierenden oder refraktären CD20-positiven follikulären B-Zell-Non-Hodgkin-Lymphoms. Nuklearmedizin 2004; 43: 171-6.
13. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Blood 2004; 104: 897.
14. Gas-, Elektrizitäts- und Wasserwerk Köln: www. gewkoelnag.de
15. Ghielmini M, Schmitz S-FH, Cogliatti S et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 2002; 100: 161a.
16. Gordon LI, Molina A, Witzig T et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429-31.
17. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc Am Soc Clin Oncol 2002; 21: 266a.
18. Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98-101.
19. Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphatic leukaemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746-51.
20. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003; 30 (Suppl 17): 29-34.
21. 90Y) ibritumomab tiuxetan (Zevalin®) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT). Blood 2004; 104: 5238.
22. Kaminski MS, Tuck M, Regan D et al. High response rate and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine-131 tositumomab (Bexxar). Blood 2002; 11: 356a.
23. Knox S, Goris M, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1999; 2: 457-70
24. Morschhauser F, Huglo D, Martinelli G et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 2004; 104: 130.
25. Nademanee A, Molina A, Forman SJ et al. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 2002; 100: 182a: 679.
26. Noßke D. Retentions- und Ausscheidungsdaten sowie Dosiskoeffizienten für die Inkorporationsüberwachung. BfS-SG-02/03, Salzgitter: Bundesamt für Strahlenschutz 2003.
27. 90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2004; 104: 2632.
28. Rodel R, Ebert A, Reichmann K et al. Effizienz von Spritzenabschirmungen bei Radionuklidanwendung zur Radiosynoviorthese. Nuklearmedizin 2003; 42: 50-3.
29. Roeder N. Anpassungsbedarf der Vergütung von Krankenhausleistungen für 2005. Gutachten im Auftrag der Deutschen Krankenhausgesellschaft. Münster 2004. www.uni-muenster.de/index.html
30. 90Y ibritumomab tiuxetan (Zevalin) radioimmuntherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 2002; 21: 267a (1064).
31. Schilder RJ, Witzig TE, Flinn I et al. Yttrium 90 ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL). Blood 2004; 104: 2629.
32. 90Y-ibritumomab tiuxetan. J Nucl Med 2004; 45: 450-4.
33. Spies SM. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Sem Nucl Med 2004; 34 (Suppl 1): 10-3.
34. Staak JO, Dietlein M, Engert A et al. Nuklearmedizinische Aspekte in der Diagnostik und Therapie des Hodgkin-Lymphoms. Nuklearmedizin 2003; 42: 19-24.
35. Strahlenschutz in der Medizin. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung). Bundesanzeiger 207a vom 7.11.2002.
36. Strahlenschutzkommission. Strahlenschutz bei der Therapie mit β-Strahlern in flüssiger Form im Rahmen einer Brachytherapie, Radiosynoviorthese der Strahlenschutzkommission am 31.3./1.4. 2003.
37. Sweetenham JW, Dicke K, Arcaroli J et al. Efficacy and safety of yttrium 90 ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 2004; 104: 2633.
38. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43: 267-72.
39. 90Y ibritumomab tiuxetan (Zevalin®, 90YZ) doses higher than .4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: the role for dosimetry. Blood 2004; 104: 1162.
40. Wiseman G, Leigh B, Witzig T et al: Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 28: 1198, 2001.
41. 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma. J Nucl Med 2001; 42: 268P.
42. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-42.
43. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465-74.
44. Wiseman GA, Colgan JP, Micallef IN et al. Interim safety results of a phase I trial of two sequential doses of yttrium-90 ibritumomab tiuxetan for previously treated patients with low-grade non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2003; 22: 575 (2312).
45. 90Y ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Blood 2004; 104: 2634.
46. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63.
47. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmuntherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-9.
48. Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmuntherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263-70.
49. Witzig TE, White CA, Wiseman GA et al. Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for treatment of relapsed or refractory CD 20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-803.
50. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure β-ray emitters. J Nucl Med 1999; 40: 1024-8.
51. Zimmer AM. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Sem Nucl Med 2004; 34 (Suppl 1): 14-9.
52. Zimmer AM, Carey AM, Spies SM. Effectiveness of specific vial shields in reducing radiation exposure from Y-90 Zevalin. J Nucl Med 2002; 43: 45P.
53. Zhu X. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). Sem Nucl Med 2004; 34 (Suppl 1): 20-3.
54. 90Y-Zevalin®). Empfehlung der Strahlenschutzkommission, verabschiedet in der 198. Sitzung der SSK am 17.2.2005.